Introduction

Pulmonary fibrosis is considering a long-standing irre- 
cable advanced interstitial lung disease with poorly outcome 
leading to high rates of morbidity and mortality [1]. It is 
considered to be the most important complication of chemo-
therapeutic agents [2].

Role of nuclear factor-kappa B in bleomycin 
induced pulmonary fibrosis and the probable alleviating role of ginsenoside: histological, 
immunohistochemical, and biochemical study

Dalia Refaat El-Bassouny, Nesreen Mostafa Omar, Hanaa Attia Khalaf, Reem Ahmad Abd Al-Salam
Medical Histology and Cell Biology Department, Faculty of Medicine, Mansoura University, El Mansoura, Egypt

Abstract: Bleomycin (BLM) is one of anti-cancerous drugs. One of its limitation is the development of pulmonary fibrosis during therapy So, we proposed to examine the outcome of BLM take on the light and electron microscopic design of rat lung. Along with, assessment the probable protecting role of ginsenoside on BLM induced pulmonary changes. In this study, thirty adult male albino rats were comprised and were classified to four clusters; Negative & positive control group, BLM treated group and BLM& ginsenoside treated group. The lung was treated for histological and immunohistochemical (anti-p65) studies. Light microscopic examination of H&E stained sections of BLM treated group showed huge distortion of the lung building. Mallory trichrome stain of this group showed evident deposition of collagen fibers in the markedly thickened interalveolar septa and around intrapulmonary bronchi, bronchioles and blood vessels. Moreover, strong positive staining for nuclear factor (NF)-κB in the wall of bronchiole as well as the thickened interalveolar septa were observed. Ultrastructural inspection of lung of this group revealed muddled lung planning. Marked improvement of the lung structure and marked reduction in NF-κB immunoexpression was appeared in BLM and ginsenoside treated group. So, we concluded that co-administration of ginsenoside with BLM significantly enhanced the histological and morphometric image of the lung.

Key words: Bleomycin, Ginsenosides, Pulmonary fibrosis, Nuclear factor-kappa B

Received April 7, 2021; Revised June 17, 2021; Accepted August 9, 2021

It is accompanying with an average survival rate of not more than 3 years. This disease is characterized by damage of alveolar lining cells, epithelial-mesenchymal transition, activation and accumulation of fibroblasts as well as myo-

fibroblasts leading to increased deposition of extracellular matrix (ECM) within the lung parenchyma [3]. The disease is also associated with infiltration of the lung tissue by many inflammatory cells including neutrophils and eosinophils in association with increased synthesis of connective tissue and inhibition of proteases [4, 5]. These changes lead to complete destruction of the alveolar histoarchitecture ended by respira-

tory failure [6].

Bleomycin (BLM) is one of anti-cancerous drugs. It is re-
currently used in treating various types of cancers like testic-
ular, prostate, ovarian, breast and cervical tumor. One of the limitations of BLM usage is the development of pulmonary fibrosis during the course of therapy [7-9].

BLM causes oxidative stress, increases the production of pro-inflammatory cytokines and activation of fibroblasts causing complete alteration and damage of pulmonary structures that finally ended by pulmonary fibrosis [10].

The use of herbs in medical purposes is considered as an alternative medicine. Herbs were the main sources of many important drugs and have been the model for many synthetic agents [11, 12].

Ginsenoside is the major bioactive component mined from the root of Panax ginseng, which is frequently used in treatment of respiratory, gastrointestinal and cardiovascular diseases [13]. Pharmacological actions of ginsenoside have been confirmed in central nervous system and cancer countering anti-stress and anti-oxidant activities [14].

Ginsenoside has anti-fibrotic, anti-inflammatory, anti-oxidant [15, 16] and anti-tumor effects [17]. Previous studies showed that ginsenoside has immunomodulatory effects that can be used for management of several immune system disorders and also attenuates lung inflammation and prevents the development of pulmonary fibrosis in rats [18, 19].

Many researches were established in the expectation of discovery a treatment that can deliberate disease evolution and hence advance survival of pulmonary fibrosis. However, pulmonary fibrosis remains a challenging disease to manage. As a result, there is an urgent need for new modulators of pulmonary fibrosis which interfere with the pathogenesis of the disease and prevent tissue remodeling [20, 21]. So, we proposed to examine the outcome of BLM take on the light and electron microscopic design of rat lung. Along with, assessment the probable protecting role of ginsenoside on BLM induced pulmonary changes.

**Materials and Methods**

**Chemicals**

BLM sulphat (bleocip): Bleomycin sulphate 15 mg ampoule (bleocip) was purchased from Cipla pharmaceutical company (Lower Parel, Mumbai, India).

Ginsenoside (ginseng): Ginsenoside 100 mg capsule (ginseng) was purchased from PHARCO pharmaceuticals Company (Alexandria, Egypt).

Nuclear factor-kappa B (NF-κB) (p65) rabbit Polyclonal Antibody Kits (catalog no. 14-6731): It was purchased from Thermo Fisher Scientific Co., Waltham, MA, USA.

**Experimental animals**

All rats’ experimental protocols and procedures were performed authorizing to the international guidelines for the use of laboratory animals and acquired the Mansoura Faculty of Medicine Institutional Research Board (MFM-IRB) approval (with code number: MS/17.07.93). The duration of the experiment was 5 weeks. Thirty adult male albino rats (180–200 g) were involved in this study. Animals were put in plastic coops under hygiene conditions of aeration and temperature with ordinary laboratory nourish and water *ad libitum*. Rats were classified to four clusters.

**Group I: negative control group**

Included 5 rats, received 0.5 ml of isotonic saline two times/week (by intraperitoneal injection) and normal saline (via orogastric tube) once daily, all for 4 weeks.

**Group II: positive control group**

Included 5 rats received 0.5 ml of isotonic saline two times/week by intraperitoneal injection followed by 80 mg/kg ginsenoside dissolved in normal saline (via orogastric tube) once daily for 4 weeks [18, 22].

**Group III: BLM treated group**

Included 10 rats received 0.5 mg of bleomycin sulphate (bleocip ampoule) dissolved in (0.5 ml) isotonic saline injected intraperitoneal (IP) two times/week for four weeks [23].

**Group IV: BLM & ginsenoside treated group**

Included 10 rats received BLM injection like group III and ginsenoside (in a dose as group II) for one week before BLM injection and then concomitant with BLM injection (for 4 weeks).

**Methods**

On the day next the latest dosage, rats were deadened with intraperitoneal injection of sodium pentobarbital (40 mg/kg) [24]. The animals were perfused via the left ventricle with 500 ml 10% neutral buffered formalin. The lung was quickly separated and processed for histological and immunohistochemical studies.

**Histological study**

Left lung were excised and were put in 10% neutral buff-
ered formalin (for fixation) and treated for light microscopic examination. Paraffin block obtained, sectioned (4–5 μm) and stained with hematoxylin and eosin (H&E) stain [25], Mallory’s trichrome stain [26].

**Immunohistochemical stain**

Avidin-biotin complex technique was used [27]. Samples were riding on positively charged slides, deparaffinization and rehydration were performed. Antigen retrieval for uncovering of antigens was performed by heating the sections in 10 mmol/L citrate buffer, (at pH 6) for two cycles. Hydrogen peroxide (3%) for 5 minutes were added to prevent the endogenous peroxide activity. The sections were incubated for 30 minutes with the primary monoclonal antibody, anti p65 (Thermo Fisher Scientific Co.) at dilution of 1:100 via phosphate buffered saline (PBS). Then, sections were bathed with PBS several times. Biotinylated goat linker was applied to the sections for 30 minutes (Thermo Scientific Co., Cheshire, UK), incubated with the avidin-biotin compound, then with peroxidase substrate solution for 5 minutes to mask the endogenous peroxide. Counterstain with Mayer’s hematoxylin was done. Negative control slides were put under the same circumstances after omitting the 1ry Ab with PBS [25]. Spleen sections used to evaluate the positivity of the tissue sections.

**Electron microscopy (TEM)**

Small fragments of right lungs were fixed in 2.5% buffered glutaraldehyde then post fixed with osmium tetroxide, dehydrated, cleared and then infiltrated in epoxy resin [28]. Semi-thin sections (cut at 1 μm) were obtained and stained with toluidine blue. Ultrathin sections were sectioned and stained with uranyl acetate and lead citrate then examined using a JEOL transmission electron microscope (100 CX; Tokyo, Japan) at the Faculty of Science, Alexandria University, Alexandria, Egypt.

**Computer assisted digital image analysis**

Slides were photo’d by Olympus® digital camera (E24-10 M pixel, China) connected to Olympus® microscope with 0.5 X photo adaptor. The outcome pictures were studied on Intel® Core i3® created computer via Video Test Morphology® software (Saint Petersburg, Russia) by a built-in routine for calibrated mechanized item study. We used it to measure width of the interalveolar septa (H&E stained sections), percentage area of collagenous fibers (Mallory trichrome stained section), percent area of NF-κB immunoreaction (NF-κB stained sections) and number of type II pneumocytes (semi-thin sections).

**Biochemical study**

Lung samples were quickly isolated, perfused with PBS (pH 7.4) and with heparin to eradicate any red blood cells then centrifuge after instantly homogenized in potassium phosphate (pH 7.5). The supernatants were gotten and used for detection of superoxide dismutase (SOD) [29], catalase (CAT) [30], and level of malondialdehyde (MDA) [31].

**Statistical analysis**

The morphometric data and biochemical were evaluated via the computer program SPSS (statistical package for social science) version 20 (IBM Corp., Armonk, NY, USA). The meaning of difference was tested using ANOVA (Analysis of Variance) followed by post-hoc Tukey for many evaluations. Values are presented as mean±SD. P-value ≤0.05 was considered statistically significant [32].

**Results**

**BLM induced marked distortion of lung architecture and ginsenoside reversed the effects**

Light microscopic inspection of lung of control group sections stained with H&E displayed the standard systematized histological building of the lung. The alveoli were inflated (Fig. 1A). The bronchioles mucosa was creased and lined by columnar epithelium. Circular smooth muscle layer lied around the mucosa while adventitia was built of loose connective tissue (Fig. 1A). The intrapulmonary bronchi wall was designed of mucosa, musculara and adventitia. The mucosa was lined by pseudostratified columnar ciliated epithelium with few goblet cells. The smooth muscle layer was spirally arranged around the mucosa. Adventitia, the outmost coat, exhibited plates of hyaline cartilage with normal chondrocytes some of them formed cell nest (Fig. 1B).

Light microscopic examination of H&E stained sections of BLM treated group revealed huge distortion of the lung building. Most of the alveoli appeared collapsed with few emphysematous ones. The interalveolar septa were markedly thickened with mononuclear cellular infiltration. Obvious dilated, congested and thickened blood vessels were observed (Fig. 1C). The wall of the bronchioles was markedly distorted with appearance of intraluminal cellular debris. The epi-
The epithelium showed massive distortion with focal stratification. Smooth muscle layer was thickened and focally interrupted by massive peribronchiolar lymphocytic infiltration (Fig. 1C). The intrapulmonary bronchi showed massive distortion and thickening of its epithelial lining with focal stratification and intraluminal cellular fragments. Manifested mononuclear infiltration in the lamina propria and adventitia was seen. The cartilage plate in the adventitia showed degeneration of...
the chondrocytes with absent nuclei (Fig. 1D).

Light microscopic inspection of H&E stained sections of BLM and ginsenoside treated group exhibited planned lung architecture. Most of the alveoli appeared intact and inflated. The interalveolar septa appeared thin with focal thickenings and mononuclear cellular infiltration. The wall of blood vessels appeared normal (Fig. 1E). Intact epithelial lining of the bronchioles was observed with minimal peribronchiolar cellular infiltration and normal circular smooth muscle layer (Fig. 1E). The wall of the intrapulmonary bronchi appeared intact with normal epithelial lining. Slight mononuclear cellular infiltration was found in the lamina propria and the smooth muscle layer appeared thin. Intact hyaline cartilage plate in the adventitia appeared with normal chondrocytes (Fig. 1F).

**BLM induced pulmonary fibrosis and ginsenoside attenuate this effect**

Light microscopic inspection of Mallory’s trichrome stained sections of control groups showed fine collagen fibers in the interalveolar septa and around intrapulmonary bronchi, bronchioles and blood vessels (Fig. 2A, B). BLM

![Figure 2](https://doi.org/10.5115/acb.21.068)

Fig. 2. Figure showed photos of mallory trichrome-stained lung sections. (A, B) Control sections: (A) Fine collagen fibers is observed in the interalveolar septa (arrows), around bronchioles (B) and blood vessels (V). (B) Fine collagen fibers (arrows) is detected in the lamina propria and adventitia of the intrapulmonary bronchi. (C, D) Bleomycin (BLM) treated sections: (C) Massive deposition of collagen fibers in the thickened interalveolar septa (arrows), in the wall of bronchioles (B) and blood vessels (V) and around them. (D) Massive deposition of collagen fibers (arrows) in the lamina propria and adventitia of the intrapulmonary bronchi and around the blood vessel (V). (E, F) BLM & ginsenosides treated sections: (E) Mild deposition of collagen fibers in the interalveolar septa (arrows), around bronchioles (B) and blood vessels (V). (F) Minimal deposition of collagen fibers (arrows) in the lamina propria and adventitia of the intrapulmonary bronchi show. (A, C, E) ×100; (B, D, F) ×400.
treated group showed huge deposition of collagen fibers in the thickened interalveolar septa and around intrapulmonary bronchi, bronchioles and blood vessels (Fig. 2C, D). On the other hand, BLM and ginsenoside treated group showed mild collagen fibers deposition in the interalveolar septa and around intrapulmonary bronchi, bronchioles and blood vessels (Fig. 2E, F).

**BLM increased NF-κB immunoexpression in the lung and ginsenoside reverse this effect**

Light microscopic examination of anti-NF-κB stained sections of control groups showed negative immune-expression of NF-κB in the bronchiole and minimal expression in the interalveolar septa (Fig. 3A). BLM treated group showed strong positive staining for NF-κB in the mucosa and adventitia of bronchiole as well as the thickened interalveolar septa (Fig. 3B, C). However, BLM and ginsenoside treated group revealed mild NF-κB immuno-expression in the mucosa and adventitia of bronchiole as well as the interalveolar septa (Fig. 3C).

**BLM increased pneumocyte type II population and ginsenoside reverse the effect**

Examination of semi-thin sections of lung of control rats showed inflated alveoli separated by interalveolar septa. These alveoli were lined by type I and type II pneumocytes.

---

![Fig. 3.](https://doi.org/10.5115/acb.21.068) (A) Control sections show negative immune-expression of anti NF-κB stain in the bronchioles (B) and very minimal expression in the interalveolar septa (arrows). (B) Bleomycin (BLM) treated sections show strong positive anti NF-κB stain expression in the interalveolar septa (arrows) and in the mucosa, musculosa & adventitia (arrows) of the bronchial wall (B). (C) BLM & ginsenosides treated sections show mild anti NF-κB stain expression in the interalveolar septa (arrows) and in the bronchioles (B).

![Fig. 4.](https://doi.org/10.5115/acb.21.068) (A) Control sections show lung alveoli (A) lined by type I (PI) and II (PII) pneumocytes. Interalveolar septa is formed of thin (arrows) and thick portions (zigzag arrows) and show few macrophage (M) with the presence of blood capillaries (C) lined by endothelial cells (E). (B) Bleomycin (BLM) treated sections show collapsed alveoli (A), thick septa (arrow) and congested blood capillaries (C). Mononuclear cellular infiltration including alveolar macrophage (M), lymphocytes (L) and neutrophils (N). Few type I pneumocytes (PI) & numerous type II (PII). (C) BLM and ginsenosides treated sections show inflated alveoli (A) lined by type I (PI), II (PII) pneumocytes and some macrophage (M). They are separated by slightly thickened interalveolar septa (arrows) with mild congested blood capillaries (C).
Few alveolar macrophages were seen. Blood capillaries lined by endothelial cells were also seen (Fig. 4A). Semithin sections of the lung of BLM treated group rats showed markedly distorted lung field with collapsed alveoli and thick interalveolar septa. The blood capillaries appeared congested. There was extensive infiltration by inflammatory cells including alveolar macrophages, lymphocytes and neutrophils. Numerous type II pneumocytes were detected (Fig. 4B). Semithin sections of the lung of BLM and ginsenoside treated group showed inflated alveoli with slightly thickened interalveolar septa. The blood capillaries were mildly congested. Mild increase of type II pneumocytes and some macrophages were observed (Fig. 4C).

**BLM induced marked distortion of lung ultrastructure and ginsenosides attenuate this effect**

Examination of ultrathin sections of studied groups; showed systematized lung field of the control group. Inflated alveoli were lined by type I and type II pneumocytes. They were disconnected by interalveolar septa (with its thin and

---

**Fig. 5.** Photos of ultrathin sections of lung sections. (A, B) Control sections: (A) Lung alveoli (A) are lined by type I (PI) and type II (PII) pneumocytes. The alveoli are separated by interalveolar septa, formed of thin (arrows) & thick portions (zigzag arrow) with the presence of blood capillaries (C) lined by endothelial cells (E). (B) Lung alveoli (A) separated by interalveolar septa (arrow) with minimal collagen fiber (CO) and blood capillaries (C). (C, D) Bleomycin (BLM) treated sections: (C) Collapsed alveoli (A), thickened interalveolar septa (arrows) with congested blood capillaries (C) and distorted endothelial lining (E) are seen. (D) Collapsed lung alveoli (A) are separated by thickened interalveolar septa (arrows) with massive collagen fiber deposition (CO). (E, F) BLM & ginsenosides treated sections: (E) Intact & inflated alveoli (A) separated by thin interalveolar septa (arrows) with mild congested blood capillaries (C). The alveoli are lined by type I (PI) & type II (PII) pneumocytes with its characteristic lamellar bodies (LB). (F) Inflated Lung alveoli (A) separated by interalveolar septa (arrows) with mild collagen fiber (CO) deposition. (A, C, E) ×6,000; (B, D, F) ×20,000.
thick parts) with minimal collagen fiber deposition. The capillaries lined by endothelial cells and contained RBCs (Fig. 5A, B). On the other hand, ultrastructural inspection of BLM treated group revealed muddled lung planning. Most of the alveoli were collapsed with the appearance of cellular debris. The interalveolar septa were markedly thickened with intensive collagen fiber deposition. The blood capillaries were obviously congested with distorted endothelium (Fig. 5C, D).

Ultrastructural inspection of lung of BLM and ginsenoside treated group showed noticeable improvement in the lung building. Majority of the alveoli are inflated. The interalveolar septa are thin with mild collagen fiber deposition and

Fig. 6. Photos of ultrathin sections of lung sections. (A, B) Control sections: (A) Type I pneumocyte has large oval euchromatic nuclei (N) and little cytoplasm contain few mitochondria (M) and rough endoplasmic reticulum (rER) (arrows). (B) Type II pneumocyte has large rounded euchromatic nuclei (N) with prominent nucleolus (n) and cytoplasm contain mitochondria (M) and rER (arrows), Golgi apparatus (tailed arrows) and lamellar bodies (LB) with their characteristic closely packed concentric lamellae. It covered by intact short microvilli (curved arrow). (C, D) Bleomycin (BLM) treated sections: (C) Degenerated type I pneumocyte with thickened basement membrane (BM) by collagen deposition (CO), it has irregular nuclei (N) and little cytoplasm contain degenerated mitochondria (M), slightly dilated rER (arrow) and vacuolations (V). (D) Distorted type II pneumocytes with damage of its surface microvilli (curved arrow). It has heterochromatic nucleus (N), its cytoplasm contains degenerated mitochondria (M) with absent cristae, excess collagen fiber deposition (CO) and degenerated lamellar bodies (LB) with loss of its concentric lamellae. (E, F) BLM and ginsenosides treated sections: (E) Type I pneumocyte has large flat regular euchromatic nuclei (N) and little cytoplasm contain few mitochondria (M) and rER (arrow). Thin interalveolar septa (thick arrow) with mild collagen deposition (CO) is seen. Note, the presence of intact blood air barrier (Br). (F) Type II pneumocyte has large rounded euchromatic nuclei (N), its cytoplasm contains intact mitochondria (M) rER (arrow), and lamellar bodies (LB) with their characteristic closely packed concentric lamellae. It covered by intact short microvilli (curved arrow). (A, C, E) ×25,000; (B, D, F) ×20,000.
containing mildly congested blood capillaries (Fig. 5E, F).

Electron microscopic picture of type I pneumocytes of control groups seemed flat and had large oval nuclei. The cytoplasm was contained few organelles as few mitochondria and few cisternae of rough endoplasmic reticulum (rER) (Fig. 6A). Type II pneumocytes of this group appeared cuboidal in shape, bulging into the alveolar lumen with short microvilli covering the cell surface. It had large rounded euchromatic nucleus with prominent nucleoli. Its cytoplasm contained mitochondria, cisternae of rER, sacculles of Golgi apparatus and lamellar bodies with the characteristic closely packed concentric lamellae (Fig. 6B). Whereas, type I pneumocytes of BLM treated group were distorted with irregular heterochromatin nuclei. The cytoplasm showed shrunken mitochondria and dilated cisternae of rER with the presence of small vacuolations. Its basement membrane was markedly thickened by the extensive deposition of collagen fibers (Fig. 6C). Type II pneumocytes of this group were damaged with small irregular and heterochromatic nuclei. The cytoplasm showed electron dense mitochondria with disrupted cristae. The lamellar bodies showed degenerative changes leaving irregular empty vacuoles with loss of the concentric lamellae. The short microvilli covering the cell surfaces were damaged (Fig. 6D). On the other hand, type I pneumocytes seemed intact with euchromatic nuclei and intact organelles (Fig. 6E). Type II pneumocytes appeared slightly intact with large euchromatic nucleus and numerous short microvilli covering the cell surface. Their cytoplasm showed intact organelles and lamellar bodies with the appearance of the characteristic concentric lamellae (Fig. 6F).

**Image analysis results and statistical analysis**

**BLM induced marked thickening of the interalveolar septa and ginsenoside attenuate this effect**

The thickness of the interalveolar septa of BLM treated
group showed highly significant increase when matched with that of control group ($P<0.0001$); and highly significant decrease when matched with that of BLM and ginsenoside treated group ($P<0.0001$) (Fig. 7A).

**BLM induced marked increase in the % area of the collagen fibers and ginsenoside attenuate this effect:** *(Mallory’s trichrome stained sections)*

The percentage area of the collagen fibers of BLM treated group showed highly significant increase when matched with that of control group ($P<0.0001$); and highly significant decrease when matched with that of BLM and ginsenoside treated group ($P<0.0001$) (Fig. 7B).

**BLM induced marked increase in the % area of the positive reaction in NF-κB immunohistochemical stained sections and ginsenoside attenuate this effect**

The percentage area of positive NF-κB immune reaction of BLM treated group showed highly significant increase when matched with that of control group ($P<0.0001$); and highly significant decrease when matched with that of BLM and ginsenoside treated group ($P<0.0001$) (Fig. 7C).

**BLM induced marked increase in the number of type II pneumocytes and ginsenoside attenuate this effect**

The mean number of types II pneumocytes of BLM treated group showed highly significant increase when matched with that of control group ($P<0.0001$); and highly significant decrease when matched with that of BLM and ginsenoside treated group ($P<0.0001$) (Fig. 7D).

**BLM induced marked changes in the oxidative stress markers and ginsenoside attenuate this effect**

A highly significant increase in the MDA ($P<0.0001$) and high significant decrease of other oxidative stress markers (CAT, SOD) levels ($P<0.0001$) in the lung tissue of BLM treated group were detected when matched with that of control group. While, a high significant decrease of MDA ($P<0.0001$)

![Fig. 8. Oxidative markers of the studied groups. (A) Mean malondialdehyde (MDA) levels in the lung tissue of the studied groups. (B) Mean catalase (CAT) levels in the lung tissue of the studied groups. (C) Mean superoxide dismutase (SOD) levels in the lung tissue of the studied groups. *Statistically significant ($P<0.0001$).](https://doi.org/10.5115/acbj.21.068)
and highly significant increase in CAT, SOD (P<0.0001) were also detected when matched with that of BLM and ginsenoside treated group (Fig. 8).

Discussion

BLM is a commonly used chemotherapeutic agent. It is either used as a single agent or in combinations with other chemotherapeutic agents. BLM causes massive lung injury and fibrosis. The animal model of lung fibrosis induced by BLM resembles what occurs in human, so it is used in studying the mechanisms which cause rapid progression of the disease [33-35].

Ginseng has anti-inflammatory and antioxidant actions. It protects against lung injury and fibrosis so improves lung functions [36]. Consequently, the existing work tried to assess the probable protective role of ginsenosides in BLM induced lung fibrosis.

In the current study, four weeks of BLM administration resulted in massive pulmonary changes. Majority of lung alveoli were collapsed with some emphysematous ones. The interalveolar septa were markedly thickened with evident mononuclear cellular infiltrations. Such findings coincide with those observed by Altintas et al. [37] and Tian et al. [38]. The thickening of interalveolar septa was statistically confirmed and coincides with that found by Tang et al. [39].

This noticeable thickening may be due to increased deposition of collagen fibers which is confirmed by Mallory trichrome stained sections and statistically by the high significant rise in the percentage area of collagen fiber matched with that of control rats. Moreover, this thickening may be the cause of collapsed alveoli. Additionally, collapsed alveoli may be also due to vascular congestion and depletion of the pulmonary surfactant [40, 41]. However, the presence of dilated alveoli could be result of epithelial, endothelial and basement membrane damage [42, 43].

The intrapulmonary bronchi and bronchioles of BLM administrated group showed marked distortion in their walls with thickening of their smooth muscle layer and extensive mononuclear cellular infiltration with degeneration of the chondrocytes of the hyaline cartilage plate. These changes are consistent with that of [44, 45].

Liu et al. [46] reported that the production of inflammatory agents as transforming growth factor beta (TGF-β) and tumor necrotic factor alpha (TNF-α) has a vital role in the proliferation and thickening of smooth muscle layer. Zaafan et al. [47] stated that BLM initiates oxidative stress with consequent increased production of reactive oxygen and nitrogen species. These oxidants stimulate many genes associated with cell growth and cell death. BLM also increases the production of pro-inflammatory agents as interleukin (IL)-6 and proteolytic enzymes leading to lipid peroxidation of the cell and defect in synthesis and degradation of lung prostaglandins [37, 48].

The degenerative changes of hyaline cartilage caused by BLM were mainly due to oxidative stress that lead to increase of COX-2 and prostaglandin E2 in chondrocytes causing its damage [49]. As well as, some cytokines as TNF-α, IL1 act by promoting inflammatory responses and encouraging cartilage damage [50].

Thickening of the blood vessels wall and extravasation of RBCs may be due to deviations in the vascular integrity of the lung capillary leading to damage of the endothelial barrier and impairment in capillary permeability [23, 51, 52].

Massive deposition of collagen fibers was detected in BLM administrated group around the alveoli, intrapulmonary bronchi, bronchioles, and blood vessels. These data come in line with [53, 54].

It is believed that BLM causes injury to the alveolar epithelium and its basement membrane; which is an essential step in the etiology of lung fibrosis. This injury leads to fibroblasts proliferation, marked increase in collagen deposition and accumulation of ECM proteins. As a result, interstitial edema, hemorrhage and thickened interstitium of the alveoli occur resulting in breakdown of connective tissue giving the picture of emphysema [48, 55, 56]. Moreover, many inflammatory cells migrate to and proliferate in sites of damage. These cells produce many cytokines causing more cell staffing and remodeling of matrix leading to excessive production of collagen and matrix components [57, 58]. Also, several inflammatory cytokines; especially TGF-β; are produced from the destructed lung tissue mainly through the activation of NF-κB pathway leading to production of fibroblasts [47, 48].

TGF-β can be secreted in the lung via many cells (macrophages, alveolar epithelial cells, endothelial cells, fibroblasts, as well as myofibroblasts). When activated, TGF-β leading to recruitment and proliferation of both macrophage and fibroblast [59, 60], causing more collagen deposition [55, 61].

Four weeks of BLM administration give rise to over expression of NF-κB in the lung tissue of the current work. This was confirmed by the high significant rise in the per-
percentage area of positive immune reaction in the lung of BLM treated group matched with control groups. Similar results were obtained by Kabel et al. [62].

NF-κB is a member of dimeric DNA binding transcription agents. It modifies the vital responses to cellular stress via the regulation of effector genes expression [63]. It is present in the cytoplasm of every cell and when activated translocate to the nucleus. Its activation is induced by free radical-sand toxins. Once it is activated, it regulates the expression of genes of several inflammatory agents as enzymes (COX-2 and iNOS) and many mediators (IL-1β, IL-6, TNF-α, and TGF-β), which are extremely related with the development of pulmonary fibrosis, especially TGF-β [64-66].

Toll like receptor 4 (TLR-4) is a crucial manager of the pro-inflammatory transcript NF-κB factor. Stimulation of TLR-4 signaling in fibroblasts give rise to increased collagen deposition and enhanced expression of several genes tangled in tissue repair and ECM [54].

NF-κB changes cell behavior in many ways; it regulates the transcription of large number of genes, especially those involved in immune and inflammatory responses and thus has a role in regulating inflammation, cell proliferation and apoptosis [64, 67]. Also, it acts as a significant controller of many functions including cellular proliferation; especially fibroblast; inflammation and differentiation [68, 69].

Many evidences showed that NF-κB signaling pathway can be activated by BLM and plays an important role in controlling inflammation [39, 38]. As well as it has an important role in BLM-induced pulmonary fibrosis [68, 69].

In the current work, semi thin sections of BLM treated group revealed marked rise in the quantity of types II pneumocytes and it was confirmed statistically. This could be attributed to destruction of type I pneumocytes with its replacement by the proliferating type II pneumocytes as the majority of the alveolar lining, type I pneumocytes, are more susceptible to injury induced by BLM [23]. Cellular infiltration with inflammatory cells was also recorded. It was reported that many inflammatory cells are involved in different stages of lung fibrosis [70].

Macrophages are the chief cells elaborated in BLM administration. They produce IL-7 which has principle action in pulmonary fibrosis [71]. Also, it has essential role in all phases of fibrosis via its extraordinary flexibility for adaptation to definite stimuli [57, 72].

In the present research, ultrastructural inspection of lung sections of BLM treated group revealed markedly thickened interalveolar septa with extensive deposition of collagen fibers and inflammatory cells infiltration. The alveoli were collapsed with the appearance of intra luminal cellular debris. Similar change was obtained by Kandhare et al. [73], Zhao et al. [74], and Zhou et al. [75].

Structural changes in both pneumocyte types were noted in the form of irregular nucleus, degenerated organelles, and cytoplasmic vacuolation in addition to degenerated lamellar bodies with loss of its concentric lamellae leaving irregular empty vacuoles. Similar observations were also recorded by others [23, 73].

Degenerative changes of organelles are explained by Hüttemann et al. [76], Liu and Chen [77] and Burman et al. [78] as adaptive processes to unfavorable conditions as excessive exposure to free radicals and hypoxia. The stressed mitochondria release cytochrome C which in turn activates caspase-9 initiating irreversible phases of apoptosis. This causes an increase in the lipid peroxidation and activation of the intrinsic pathway of apoptosis.

The cytoplasmic vacuolations might be due to the release of free radicals which alter Na/K pump role causing accumulation of sodium and migration of water to the cell. Moreover, any toxic agents may be aggregated in the form of vacuoles in the cell [79].

Changes of type II pneumocytes were linked with reduced production and release of lung surfactant as well as change in its composition and function. This defect could be attributed to ROS. The change in surfactant alters the pulmonary surface tension and lead to collapsed alveoli [23, 74].

The current work showed highly significant changes in the oxidative marker in lung tissue of BLM treated group; there was significant rise in level of MDA equivalent with a significant reduction of SOD and CAT levels matched with that of control groups. These data theorized the existence of oxidative stress in BLM treated group and it come in agreement with preceding studies [38, 80, 81].

In the existing work, lung sections of BLM and ginseng treated group showed marked improvement in lung structure more or less similar to that of control groups. The interalveolar septa were intact and thin with normal and inflated alveoli. Statistically there was high significant reduction in the thickness of the interalveolar septa of this group matched with that of BLM treated group. The epithelium of the intrapulmonary bronchi and bronchioles appeared intact with thin smooth muscle layer and minimal mononuclear cellular infiltration in the adventitia. The hyaline cartilage plate in
the adventitia appeared intact with normal chondrocytes

Similar results were obtained by Guan et al. [19] and Gao et al. [82].

In BLM and ginseng treated group, Mallory’s trichrome
stained sections revealed minimal collagen fibers deposi-
tion in the interalveolar septa and around intrapulmonary bronchi, bronchioles and blood vessels. Statistically highly significant reduction in the percentage area of collagen fibers matched with that of BLM treated group. Similar results were run with that published by Zhou et al. [83].

Mild positive immune expression for NF-κB in BLM and
ginseng treated group was detected and exhibited a high sig-
nificant reduction matched with BLM treated group. These data come in line with Shergis et al. [13], Saba et al. [84] and Ahn et al. [85].

Improvement of lung field with few inflammatory cells
and less frequent type II pneumocytes was detected in semi-
thin sections of the lung of BLM and ginseng treated group. This was confirmed by high significant reduction in the mean number of types II pneumocytes in BLM and ginseng treated group when compared with that of BLM treated group rats. This reduction may be caused by the protective effect of ginseng which prevents the damage of type I pne-
mocytes and preserves their structure and number and thus prevents proliferation of type II pneumocytes.

Remarkably improvement of the lung building of BLM
and ginseng treated group was also detected by electron mi-
scopy. The lung design was conserved; the alveoli were infla-
ated with thin interalveolar septa. Similar results were
reported by Bilgin et al. [33]. Type I and type II pneumocytes
appeared intact. Type II pneumocytes showed intact lamellar
bodies with their concentric lamellae. the cytoplasm showed
intact organelles. Similar findings were reported by Ren et al.
[86].

Ginseng has many pharmacologically bioactive ingredi-
ents including ginsenosides, polysaccharides, polyacetylenes,
phytosterols, and essential oils. Ginsenosides are the chief
active ingredients [87]. Ginsenosides have powerful antioxi-
dant and anti-inflammatory properties via scavenging free radicals and upregulation of antioxidant enzymes. Ginseng regulates inflammation through inhibition of lung patho-
logical changes including edema, cellular infiltration and the
release of inflammatory agents (TNF-α, TGF-β, IL-1β, IL-4,
and IL-6) [36, 88].

Many studies have shown that ginseng inhibits lipid per-
oxidation and NF-κB activation. The pathogenesis of fibrosis
mediated by many inflammatory agents (mainly TGF-β)
which can be inhibited by ginseng [89].

It was also reported that ginseng inhibit lipid peroxida-
tion, ameliorate the endothelial NO thus enhance endothe-

dial dysfunction [90].

Ginsenosides inhibit NF-κB activation and thus prevent
IL-1β-produced chondrocytes apoptosis and inflammation.

The pro-inflammatory cytokine IL-1β has been proved to
reduce chondrocytes viability, up-regulation of pro-apop-
totic proteins and activates NF-κB signaling pathway [91].
Moreover, previous reports have indicated that ginsenosides
inhibit TNF-α-induced NF-κB activation [92].

The current work showed highly significant reduction in
lung level of MDA equivalent with a significant rise of SOD
and CAT levels in BLM and ginseng treated group matched
with that of BLM treated group. These data consistent with
Duguran et al. [93] who studied the antioxidant defensive
potential of ginseng. It was manifested by a decrease in ROS
which is the major contributor to oxidative stress which
does tissue damage by lipid peroxidation. This increase in
lipid peroxidation was normalized or decreased by the intake
of ginseng.

So, we can concluded that, ginsenosides expressively ame-
liorated BLM-induced pulmonary fibrosis through the inhi-
bition of NF-κB activation in addition to their antifibrotic,
antioxidant and anti-inflammatory activities. So, ginseng
may be a meaningful adjuvant treatment with BLM to elimi-
nate the hazardous of pulmonary fibrosis. Further studies
are required to declare the possible mechanisms by which
ginseng could mitigate BLM induced pulmonary fibrosis.

ORCID

Dalia Refaat El-Bassouny:
https://orcid.org/0000-0002-3884-1265
Nesreen Mostafa Omar:
https://orcid.org/0000-0001-7483-4030
Hanaa Attia Khalaf:
https://orcid.org/0000-0001-6644-5422
Reem Ahmad Abd Al-Salam:
https://orcid.org/0000-0001-7013-6462

Author Contributions

Conceptualization: DREB. Data acquisition: RAAAS.
Data analysis or interpretation: NMO, HAK. Drafting of
the manuscript: DREB, NMO, HAK. Critical revision of the manuscript: DREB, NMO, HAK. Approval of the final version of the manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirid J. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016;48:843-51.

2. Liu Y, Lu F, Kang L, Wang Z, Wang Y. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med 2017;17:63.

3. Cui Y, Jiang L, Yu R, Shao Y, Mei L, Tao Y. β-carboline alkaloids attenuate bleomycin induced pulmonary fibrosis in mice through inhibiting NF-kb/p65 phosphorylation and epithelial-mesenchymal transition. J Ethnopharmacol 2019;243:112096.

4. Stoll P, Wuertemberger U, Bratke K, Zingler C, Virchow JC, Lommatzsch M. Stage-dependent association of BDNF and TGF-β1 with lung function in stable COPD. Respir Res 2012;13:116.

5. Choi SM, Jang AH, Kim H, Lee KH, Kim YW. Metformin reduces bleomycin-induced pulmonary fibrosis in mice. J Korean Med Sci 2016;31:1419-25.

6. Wang M, Zhang J, Song X, Liu W, Zhang L, Wang X, Lv C. Astaxanthin ameliorates lung fibrosis in vivo and in vitro by preventing transdifferentiation, inhibiting proliferation, and promoting apoptosis of activated cells. Food Chem Toxicol 2013;56:450-8.

7. Peng R, Sridhar S, Taji G, Phillips JE, Garrido R, Harris P, Burns L, Renteria L, Woods J, Chen L, Allard J, Ravindran P, Bitter H, Liang Z, Hogaboam CM, Kitson C, Budd DC, Fine JS, Bauer CM, Stevenson CS. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for “active” disease. PLoS One 2013;8:e59348.

8. Yao Y, Wang Y, Zhang Z, He L, Zhu J, Zhang M, He X, Cheng Z, Ao Q, Cao Y, Yang P, Su Y, Zhao J, Zhang S, Yu Q, Ning Q, Xiang X, Xiong W, Wang CY, Xu Y. Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production. Mol Ther 2016;24:915-25.

9. Gerson SL, Caimi PF, William BM, Creger RJ. Pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz J, Anastasi J, Salama ME, Abutalib SA, editors. Hematology: Basic Principles and Practice. 7th ed. Philadelphia: Elsevier Health Sciences; 2018. p.849-912.

10. Shariati S, Kalantar H, Pashmforoosh M, Mansouri E, Khoodyar MJ. Epicatechin protective effects on bleomycin-induced pulmonary oxidative stress and fibrosis in mice. Biomed Pharmacother 2019;114:108776.

11. Ballington DA, Anderson RJ. Pharmacy practice for techni-
cians. 5th ed. St. Paul: Paradigm Publishing; 2014.

12. Jamshidi-Kia F, Lorigooini Z, Amini-Khoei H. Medicinal plants: Past history and future perspective. J Hermed Pharma-
col 2018;7:1-7.

13. Shergis J, Di Y, Zhang A, Vlahos R, Helliwell R, Ye J, Xue CC. Therapeutic potential of Panax ginseng and ginsenosides in the treatment of chronic obstructive pulmonary disease. Complement Ther Med 2014;22:944-53.

14. Niranjan Murthy H, Dandin VS, Yoeup Paek K. Hepatoprotective activity of ginsenosides from Panax ginseng adventitious roots against carbon tetrachloride treated hepatic injury in rats. J Ethnopharmacol 2014;158 Pt A:442-6.

15. Bao S, Zou Y, Wang B, Li Y, Zhu J, Luo Y, Li J. Ginsenoside Rg1 improves lipopolysaccharide-induced acute lung injury by inhibiting inflammatory responses and modulating infiltration of M2 macrophages. Int Immunopharmacol 2015;28:429-34.

16. Nguyen CT, Luong TT, Lee SY, Kim GL, Kwon H, Lee H, Park CK, Rhee DK. Panax ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival and diminishing inflammation. Phytomedicine 2015;22:1055-61.

17. Wang CZ, Anderson S, DU W, He TC, Yuan CS. Red ginseng and cancer treatment. Chin J Nat Med 2016;14:7-16.

18. Chen J, Feng X, Huang Q. Modulation of T-Bet and GATA-3 expression in experimental autoimmune thyroiditis rats through ginsenoside treatment. Endocr Res 2016;41:28-33.

19. Guan S, Liu Q, Han F, Gu W, Song L, Zhang Y, Guo X, Xu W. Ginsenoside Rg1 ameliorates cigarette smoke-induced airway fibrosis by suppressing the TGF-β1/Smad pathway in vivo and in vitro. Biomed Res Int 2017;2017:6510198.

20. Behr J. The diagnosis and treatment of idiopathic pulmonary fibrosis. Disch Arztebl Int 2013;110:875-81.

21. Costabel U. The changing treatment landscape in idiopathic pulmonary fibrosis. Eur Respir Rev 2015;24:65-8.

22. Zhou J, Zhang HA, Lin Y, Liu HM, Cui YM, Xu Y, Zhao N, Ma JM, Fan K, Jiang CL. Protective effect of ginsenoside against acute renal failure via reduction of renal oxidative stress and enhanced expression of ChAT in the proximal convoluted tubule and ERK1/2 in the paraventricular nuclei. Physiol Res 2014;63:597-604.

23. Kamel EO, Hady AARA, Abd Elrahman ASAH, Diab MM. Evaluation of role of captopril and erdosteine in protection of the lung against bleomycin-induced injury in rats. Egypt J Hosp Med 2019;75:1937-45.

24. Ma H, Jo YJ, Ma Y, Hong JT, Kwon BM, Oh KW. Obovatos isolated from Magnolia obovata enhances pentobarbital-induced sleeping time: possible involvement of GABAA receptors/chloride channel activation. Phytomedicine 2009;16:308-13.

25. Bancroft JD, Layton C. The hematoxylins and eosin. In: Suvarna SK, Layton C, Bancroft JD, editors. Bancroft’s Theory and
Practice of Histological Techniques. 8th ed. London: Elsevier; 2019. p.126-38.
26. Kiernan JA. Histological and histochemical methods: theory and practice. 5th ed. Banbury: Scion; 2015.
27. Sanderson T, Wild G, Cull AM, Marston J, Zardin G. Immunohistochemical and immunofluorescent techniques. In: Suvarna SK, Layton C, Bancroft JD, editors. Bancroft’s Theory and Practice of Histological Techniques. 8th ed. London: Elsevier; 2019. p.337-94.
28. Woods AE, Stirling JW. Transmission electron microscopy. In: Suvarna SK, Layton C, Bancroft JD, editors. Bancroft’s Theory and Practice of Histological Techniques. 8th ed. London: Elsevier; 2019. p.434-75.
29. Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem 1971;44:276-87.
30. Sinha AK. Colorimetric assay of catalase. Anal Biochem 1972;47:389-94.
31. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
32. Rosner B. Fundamentals of biostatistics. 8th ed. Boston: Cengage Learning; 2015.
33. Bilgin G, Kismet K, Kuru S, Kaya F, Senes M, Bayrakceken Y, Yumusak N, Celikkan FT, Erdemli E, Celemli OG, Sorkun K, Koca G. Ultrastructural investigation of the protective effects of propolis on bleomycin induced pulmonary fibrosis. Biotech Histochem 2016;91:195-203.
34. Dong SH, Liu YW, Wei F, Tan HZ, Han ZD. Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomed Pharmacother 2017;89:1297-309.
35. Arezzini B, Vecchio D, Signorini C, Stringa B, Gardi C. F2-isoprostanes can mediate bleomycin-induced lung fibrosis. Free Radic Biol Med 2018;115:1-9.
36. Jang SS, Kim HG, Han JM, Lee JS, Choi MK, Huh GJ, Son CG. Modulation of radiation-induced alterations in oxidative stress and cytokine expression in lung tissue by Panax ginseng extract. Phytother Res 2015;29:201-9.
37. Altintas N, Erboga M, Aktas C, Bilir B, Aydin M, Sengul A, Ates Z, Topcu B, Gurel A. Protective effect of infliximab, a tumor necrosis factor-alfa inhibitor, on bleomycin-induced lung fibrosis in rats. Inflammation 2016;39:65-78.
38. Tian SL, Yang Y, Liu XL, Xu QB. Emodin attenuates bleomycin-induced pulmonary fibrosis via anti-inflammatory and anti-oxidative activities in rats. Med Sci Monit 2018;24:1-10.
39. Tang H, Gao L, Mao J, He H, Liu J, Cai X, Lin H, Wu T. Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways. Cell Stress Chaperones 2016;21:239-49.
40. Mazzoli-Rocha F, Carvalho GM, Lanzetti M, Valença SS, Silva LF, Saldiva PH, Zin WA, Faffe DS. Respiratory toxicity of repeated exposure to particles produced by traffic and sugar cane burning. Respir Physiol Neurobiol 2014;191:106-13.
41. Rago F, Melo EM, Kraemer L, Galvão I, Cassali GD, Santos RAS, Russo RC, Teixeira MM. Effect of preventive or therapeutic treatment with angiotensin 1-7 in a model of bleomycin-induced lung fibrosis in mice. J Leukoc Biol 2019;106:677-86.
42. Li L, Li D, Xu L, Zhao P, Deng Z, Mo X, Li P, Qi L, Li J, Gao J. Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine 2015;22:111-9.
43. Meng L, Zhang X, Wang H, Dong H, Gu X, Yu X, Liu Y. Yang-yin Yiqi Mixture ameliorates Bleomycin-induced pulmonary fibrosis in rats through inhibiting TGF-β1/Smad pathway and epithelial to mesenchymal transition. Evid Based Complement Alternat Med 2019;2019:2710509.
44. Chen F, Wang PL, Fan XS, Yu JH, Zhu Y, Zhu ZH. Effect of Renshen Pinglei Decoction, a traditional Chinese prescription, on IPF induced by Bleomycin in rats and regulation of TGF-β1/Smad3. J Ethnopharmacol 2016;186:289-97.
45. Tawfik MK, Makary S. 5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: comparison to terguride. Eur J Pharmacol 2017;814:114-23.
46. Liu J, Han Z, Han Z, He Z. Mesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension. Exp Ther Med 2016;11:467-75.
47. Zaaafan MA, Zaki HF, El-Brairy AI, Kenawy SA. Pyrrolidinedithiocarbamate attenuates bleomycin-induced pulmonary fibrosis in rats: modulation of oxidative stress, fibrosis, and inflammatory parameters. Exp Lung Res 2016;42:408-16.
48. Zuo WL, Zhao JM, Huang JX, Zhou W, Lei ZH, Huang YM, Huang YF, Li HG. Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis. Biomed Rep 2017;6:201-5.
49. Goto K, Imaoka M, Goto M, Kituchi I, Suzuki T, Jindo T, Takasaki W. Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats. Toxicol Lett 2013;216:124-9.
50. Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, Huang H, Liu P, Shen X. Inhibitory effect of the anti-malarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Trans Res 2013;161:89-98.
51. Li Q, Mao M, Qiu Y, Liu G, Sheng T, Yu X, Wang S, Zhu D. Key role of ROS in the process of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid-mediated pulmonary vascular remodeling in hypoxia pulmonary hypertension. PLoS One 2016;11:e0149164.
52. Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L. Reactive oxygen species: key regulators in vascular health and diseases. Br J Pharmacol 2018;175:1279-92.
53. Verma R, Kushwah L, Gohel D, Patel M, Marvania T, Balkrishnan S. Evaluating the ameliorative potential of quercetin against the bleomycin-induced pulmonary fibrosis in Wistar rats. Pulm Med 2013;2013:921724.
54. Sabry M, Taha HH, Mohamed AO, Thabet K, Hasan AA, Abdel-Razik ARH, Elsadek BEM. TLR4/NF-KB signaling pathway is a key pathogenic event of lung injury in bleomycin-induced pulmonary fibrosis in a mouse model. Az J Pharm Sci 2020;61:92-103.

55. Kato S, Inui N, Hakamata A, Suzuki Y, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T. Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. Respir Res 2018;19:127.

56. Qin X, Yan M, Wang X, Zhu X, Shi J, Li Z, Zhang J, Chen W. Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the Osteopontin-NF-kappa B signaling pathway. Theranostics 2018;8:921-40.

57. Wu J, Ding J, Yang J, Guo X, Zheng Y. MicroRNA roles in the nuclear factor kappa B signaling pathway in cancer. Front Immunol 2018;9:546.

58. Zhao L, Mu B, Zhou R, Cheng Y, Huang C. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice: Comparison of bleomycin-induced lung fibrosis. Toxicology 2018;393:185-92.

59. Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corno M, Kato S, Inui N, Hakamata A, Suzuki Y, Enomoto N, Fujisawa T, Nakamura Y, Watanabe H, Suda T. Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis in mice: ANP for pulmonary fibrosis. Respir Res 2017;18:1.

60. Okamoto A, Nojiri T, Konishi K, Tokudome T, Miura K, Hosoda H, Hino J, Miyazato M, Asai K, Hirata K, Kangawa K. Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis. Respir Res 2017;18:1.

61. Aaraf MH, Mohamed DA, Atteha HH. Ameliorative effect of Glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-kB, Muc5ac, TNF-α and IL-1β. Chem Biol Interact 2015;237:151-65.

62. Zhao Q, Wu J, Lin Z, Hua Q, Zhang W, Ye L, Wu G, Du J, Xia J, Chu M, Hu X. Resolvin D1 alleviates the lung ischemia reperfusion injury via complement, immunoglobulin, TLR4, and inflammatory factors in rats. Inflammation 2016;39:1319-33.

63. Zhou Z, Kandhare AD, Kandhare AA, Bodhankar SL. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IκBα/IKK signal pathways. EXCLI J 2019;18:723-45.

64. Hettemann M, Helling S, Sanderson TH, Sinkler C, Samavati L, Mahapatra G, Varughese A, Lu G, Li G, Ramzan R, Vogt S, Grossman LI, Doan JW, Marcus K, Lee I. Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/ reperfusion injury and inflammation. Biochem Biophys Acta 2012;1817:598-609.

65. Liu X, Chen Z. The pathophysiological role of mitochondrial oxidative stress in lung diseases. J Transl Med 2017;15:207.

66. Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol 2018;68-69:355-65.

67. Araba DA, Mohamed M, Atteha HH. Ameliorative effect of N-acetyl cysteine on alpha-cypermethrin-induced pulmonary toxicity in male rats. Environ Toxicol 2015;30:26-43.

68. El-Khouly D, El-Bakly WM, Awad AS, El-Mesallamy HO, El-Demerdash E. Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor kappa B in rats. Toxicology 2012;302:106-13.
81. Bahri S, Ben Ali R, Gasmì K, Mlika M, Fazaa S, Ksouri R, Serairi R, Jameleddine S, Shlyonsky V. Prophylactic and curative effect of rosemary leaves extract in a bleomycin model of pulmonary fibrosis. Pharm Biol 2017;55:462-71.

82. Gao Y, Yao LF, Zhao Y, Wei LM, Guo P, Yu M, Cao B, Li T, Chen H, Zou ZM. The Chinese herbal medicine formula mKG suppresses pulmonary fibrosis of mice induced by bleomycin. Int J Mol Sci 2016;17:238.

83. Zhou Y, Liao S, Zhang Z, Wang B, Wan L. Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-regulating Jagged1/Notch1 in lungs. J Pharm Pharmacol 2016;68:389-96.

84. Saba E, Jeon BR, Jeong DH, Lee K, Goo YK, Kwak D, Kim S, Roh SS, Kim SD, Nah SY, Rhee MH. A novel Korean red ginseng compound gintonin inhibited inflammation by MAPK and NF-κB pathways and recovered the levels of mir-34a and mir-93 in RAW 264.7 cells. Evid Based Complement Alternat Med 2015;2015:624132.

85. Ahn S, Singh P, Castro-Aceituno V, Yesmin Simu S, Kim YJ, Mathiyalagan R, Yang DC. Gold nanoparticles synthesized using Panax ginseng leaves suppress inflammatory - mediators production via blockade of NF-κB activation in macrophages. Artif Cells Nanomed Biotechnol 2017;45:270-6.

86. Ren J, Wang LX, Ji XC, Zhou JY, Zhang MY. Ultrastructural observation on pulmonary fibrosis in E9 rats treated with compound Carapax trionycis formula. Asian Pac J Trop Med 2013;6:153-5.

87. Im K, Kim J, Min H. Ginseng, the natural effectual antiviral: Protective effects of Korean Red Ginseng against viral infection. J Ginseng Res 2016;40:309-14.

88. Hsieh YH, Deng JS, Chang YS, Huang GJ. Ginsenoside Rh2 ameliorates lipopolysaccharide-induced acute lung injury by regulating the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 signaling pathways in mice. Nutrients 2018;10:1208.

89. Hafez MM, Hamed SS, El-Khadragy MF, Hassan ZK, Al-Rejaie SS, Sayed-Ahmed MM, Al-Harbi NO, Al-Hosaini KA, Al-Harbi MM, Alhoshani OA, Alsharari SD. Effect of ginseng extract on the TGF-β1 signaling pathway in CCl₄-induced liver fibrosis in rats. BMC Complement Altern Med 2017;17:45.

90. Mansour HH. Protective effect of ginseng against gamma-irradiation-induced oxidative stress and endothelial dysfunction in rats. EXCLI J 2013;12:66-77.

91. Zhang XH, Xu XX, Xu T. Ginsenoside Ro suppresses interleukin-β-induced apoptosis and inflammation in rat chondrocytes by inhibiting NF-κB. Chin J Nat Med 2015;13:283-9.

92. Rastogi V, Santiago-Moreno J, Doré S. Ginseng: a promising neuroprotective strategy in stroke. Front Cell Neurosci 2015;8:457.

93. Duguran DR, Lopez MJC, Valenzuela MTCE, Ples MB, Vitor II RJS. Protective potential of ginseng and silymarin on the liver and kidney of ethanol-treated mice (Mus musculus). Natl J Physiol Pharm Pharmacol 2018;8:969-76.